CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis

Citations Over TimeTop 10% of 2016 papers

Abstract

CD147/EMMPRIN (extracellular matrix metalloproteinase inducer) plays an important role in tumor progression and a number of studies have suggested that it is an indicator of tumor prognosis. This current meta-analysis systematically reevaluated the predictive potential of CD147/EMMPRIN in various cancers. We searched PubMed and Embase databases to screen the literature. Fixed-effect and random-effect meta-analytical techniques were used to correlate CD147 expression with outcome measures. A total of 53 studies that included 68 datasets were eligible for inclusion in the final analysis. We found a significant association between CD147/EMMPRIN overexpression and adverse tumor outcomes, such as overall survival, disease-specific survival, progression-free survival, metastasis-free survival or recurrence-free survival, irrespective of the model analysis. In addition, CD147/EMMPRIN overexpression predicted a high risk for chemotherapy drugs resistance. CD147/EMMPRIN is a central player in tumor progression and predicts a poor prognosis, including in patients who have received chemo-radiotherapy. Our results provide the evidence that CD147/EMMPRIN could be a potential therapeutic target for cancers.

Related Papers

• Matrix Metalloproteinases(MMPs)and Tissue Inhibitors of Metalloproteinases(TIMPs)in the Development and Disease of Oral Tissues(1998)
• MATRIX METALLOPROTEINASES AND METASTASIS OF LUNG CANCER(2003)
• → Changes of Serum Concentrations of Matrix Metalloproteinases,Tissue Inhibitors of Metalloproteinases and Type IV Collagen in patients with various types of glomerulonephritis(種々の糸球体腎炎患者におけるMatrix Metalloproteinases,Tissue Inhibitors of Metalloproteinases,IV型コラーゲンの血清中濃度の変化)(1997)
• Progress in study of matrix metalloproteinases and tumour invasion and metastasis(2001)
• Effects of matrix metalloproteinase on the invasion and metastasis of antitumor(2009)